Klatzmann D - Search Results

1

T cell repertoire in patients with stable scleroderma.

Tiev KP, Abriol J, Burland MC, Antonelli D, Klatzmann D, Cabane J, Boyer O. Tiev KP, et al. Among authors: klatzmann d. Clin Exp Immunol. 2005 Feb;139(2):348-54. doi: 10.1111/j.1365-2249.2004.02647.x. Clin Exp Immunol. 2005. PMID: 15654834 Free PMC article.

2

Characterization of an intronless CD4 minigene expressed in mature CD4 and CD8 T cells, but not expressed in immature thymocytes.

Salmon P, Boyer O, Lorès P, Jami J, Klatzmann D. Salmon P, et al. Among authors: klatzmann d. J Immunol. 1996 Mar 1;156(5):1873-9. J Immunol. 1996. PMID: 8596039

3

Gene therapy for HIV: from myth to reality?

Boyer O, Lemoine FM, Klatzmann D. Boyer O, et al. Among authors: klatzmann d. AIDS. 1995;9 Suppl A:S203-12. AIDS. 1995. PMID: 8819587 Review. No abstract available.

4

Gene therapy for liver tumors.

Panis Y, Rad AR, Boyer O, Houssin D, Salzmann JL, Klatzmann D. Panis Y, et al. Among authors: klatzmann d. Surg Oncol Clin N Am. 1996 Apr;5(2):461-73. Surg Oncol Clin N Am. 1996. PMID: 9019365 Review.

5

Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes.

Cohen JL, Boyer O, Salomon B, Onclercq R, Charlotte F, Bruel S, Boisserie G, Klatzmann D. Cohen JL, et al. Among authors: klatzmann d. Blood. 1997 Jun 15;89(12):4636-45. Blood. 1997. PMID: 9192790 Free article.

6

Position-dependent variegation of a CD4 minigene with targeted expression to mature CD4+ T cells.

Boyer O, Zhao JC, Cohen JL, Depetris D, Yagello M, Lejeune L, Bruel S, Mattéï MG, Klatzmann D. Boyer O, et al. Among authors: klatzmann d. J Immunol. 1997 Oct 1;159(7):3383-90. J Immunol. 1997. PMID: 9317137

7

Deletional and mutational analyses of the human CD4 gene promoter: characterization of a minimal tissue-specific promoter.

Zhao-Emonet JC, Boyer O, Cohen JL, Klatzmann D. Zhao-Emonet JC, et al. Among authors: klatzmann d. Biochim Biophys Acta. 1998 Nov 8;1442(2-3):109-19. doi: 10.1016/s0167-4781(98)00154-7. Biochim Biophys Acta. 1998. PMID: 9804915

8

A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma.

Klatzmann D, Chérin P, Bensimon G, Boyer O, Coutellier A, Charlotte F, Boccaccio C, Salzmann JL, Herson S. Klatzmann D, et al. Hum Gene Ther. 1998 Nov 20;9(17):2585-94. doi: 10.1089/hum.1998.9.17-2585. Hum Gene Ther. 1998. PMID: 9853525 Clinical Trial.

9

A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma.

Klatzmann D, Valéry CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J. Klatzmann D, et al. Hum Gene Ther. 1998 Nov 20;9(17):2595-604. doi: 10.1089/hum.1998.9.17-2595. Hum Gene Ther. 1998. PMID: 9853526 Clinical Trial.

10

Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase delta TK gene.

Cohen JL, Boyer O, Salomon B, Onclerco R, Depetris D, Lejeune L, Dubus-Bonnet V, Bruel S, Charlotte F, Mattéï MG, Klatzmann D. Cohen JL, et al. Among authors: klatzmann d. Transgenic Res. 1998 Sep;7(5):321-30. doi: 10.1023/a:1008893206208. Transgenic Res. 1998. PMID: 9859221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

373 results

Search Page